PRAME-Specific T-Cell Therapy in Advanced Pediatric Nephroblastoma

In a child with advanced nephroblastoma, T-cell therapy targeting preferentially expressed antigen in melanoma led to a 69% tumor reduction, with molecular, metabolic, and histologic evidence of complete remission at 200 days.